The hepatitis C virus (HCV) is a major public health problem due to its high prevalence, high rate of onward transmission and health complications. As many as 85% of people infected with HCV may go on to become chronic carriers of the disease with the risk of developing liver cancer or cirrhosis. At present, it is the most common cause of chronic liver disease and liver transplantation in a number of countries, with an estimated 250,000 people dying annually from HCV-related causes.
INTRODUCTION
In recent years, the hepatitis C virus (HCV) has emerged as a major threat to public health worldwide. The global disease burden of HCV is staggering, with an estimated 180 million people infected with the virus (1) . In contrast, it is estimated that 33.2 (30.6-36.1) million individuals are living with the human immunodeficiency virus (HIV) worldwide (2) . The prevalence of HCV in the general population varies substantially, from 0.5% in northern Europe to 3% in Mediterranean countries (3) , and reaching over 13% in Egypt, for example (4) . However, the data on HCV prevalence in Europe are often very limited.
The epidemiology of HIV and hepatitis coinfection is also significant, as both viruses share common routes of transmission (sharing of unsterile injecting equipment). One crucial difference, however, is the greater infectivity of hepatitis. HCV is about 10 times more infectious than HIV (5) and, consequently, exposure carries greater risk of infection. Public awareness is also low, in part because HCV often presents no symptoms. The combination of these factors contributes to the fact that the vast majority of infected people are unaware of their status.
However, HCV presents an important public health problem globally. Without diagnosis and treatment HCV causes chronic infection in up to 85% of those infected, and among those chronically infected, cirrhosis may develop in 5 to 20% of cases (6) . The scale and urgency of the HCV problem is made alarmingly clear in mortality statistics, with an estimated 250,000 people dying annually of HCV-related causes (7) . It is already the most common cause of chronic liver disease and the most common reason for liver transplantation in US and western Europe. Furthermore, morbidity and mortality rates from HCV infection are rising and are expected to continue to rise in the coming decades (6) .
This study analyses the available data on HCV prevalence in selected European countries and estimates the proportion of undiagnosed people with HCV.
MATERIALS AND METHODS
Information on reported HCV cases, the estimated prevalence both in the general population and in different risk groups, and the estimated number of undiagnosed cases was collected in three stages: The countries were selected on the basis of geographical location, with the goal of representing the different subregions of Europe (western, central and eastern Europe) while also taking into account the varying levels of economic and social development. As a result, information was obtained from 17 countries: Armenia, Belarus, Bulgaria, the Czech Republic, France, Georgia, Germany, Hungary, Italy, the Netherlands, Lithuania, Poland, Romania, Russia, Spain, Ukraine and the United Kingdom.
RESULTS
Available data for HCV confirms that HCV prevalence varies substantially among countries and suggests a higher prevalence in the countries of central and eastern Europe (Table 1) , reaching 4.9% in Romania and 6.7% in Georgia. In western Europe, the highest estimated prevalence is in Spain (2%) and Italy (3.07%).
However, current HCV prevalence data in most European countries is unrepresentative and thereby uncertain. In order to determine the number of people undiagnosed we calculated the difference between reported cases and estimated cases, if not indicated otherwise in the footnotes for Table 2 .
The availability and quality of national HCV reporting, resources and screening varies dramatically from country to country, but overall there are significant inconsistencies that exist in HCV awareness and diagnosis across Europe. Only between 10% to 40% of people with HCV know about their infection in such diverse countries as the Czech Republic, Germany, the Netherlands, Poland and the United Kingdom (for more details see Table   Table 1 2 The number of estimated cases is calculated based on the % of HCV prevalence in general population if not indicated otherwise in the footnotes to particular countries. in Germany there are an estimated 400,000-500,000 HCV cases with around 35,000-450,000 people can still be unreported. According to the National Hepatitis Centre in the Netherlands, there are about 60,000 people with chronic hepatitis C (0.37% of total population), with around 5,000 to 10,000 aware of their status (8) .
In most of the countries assessed, the infection primarily affects men and is concentrated in individuals under the age of 45. An increasing number of cases have been identified in young adults In countries with a high prevalence in older age groups, such as Italy − where 60% of estimated HCV cases are in people older than 65 years − therapeutic injections 30-50 years ago probably had a substantial role in HCV transmission (9) . A review of data for 1997 also showed that diagnostic or treatment procedures in hospitals were among the key transmission routes of HCV in the countries of central and eastern Europe in the late 1990s (e.g. approximately 59−65% of cases in Poland, 59% in Latvia and 46% in Lithuania) (10) .
Since the introduction in 1989, or shortly thereafter, of bloodand blood-product-screening in most European countries, the predominant source of new HCV infections has now become injecting drug use. This is particularly the case in countries where most newly identified cases occur in young adults. The percentage of newly diagnosed cases that can be attributed to either active injecting drug users (IDUs) or people with a history of injecting in European countries varies from 20% to 89% (11) (12) (13) (14) .
The data from countries also showed that HCV prevalence varies substantially within countries. For example, in Italy prevalence in different regions varies from 3% to over 20% (9) ; in different parts of Poland it varies from 1.2% to over 15% (15) .
DISCUSSION
Due to the diverse surveillance and reporting systems existing in countries and the fact that HCV is not a notifiable disease in some countries, the number of reported cases does not always correspond to the number of diagnosed cases. This should be taken into account when interpreting the number of undiagnosed cases.
Determining the prevalence of HCV infection is difficult because most acute infections are asymptomatic. Even in countries where HCV is notifiable by law, the number of newly diagnosed cases remains underreported. Furthermore, some countries (Hungary, Italy, Lithuania and Ukraine) do not report chronic hepatitis C cases, which means that there is lack of information about how many people are at risk of developing chronic liver diseases and how many people will eventually need hepatitis C treatment.
More data on the estimated prevalence of HCV infection is available from population-based studies performed in western Europe than for central and eastern Europe.
Awareness of HCV in the general population and among risk groups is low. This is demonstrated not only by the dramatically low proportion of people aware of their infection status, but also by the fact that most newly reported cases of HCV are of chronic hepatitis C infection, indicating a lack of timely diagnosis. For example, data from Belarus showed that half of the reported cases in 2006 were for chronic hepatitis C (16); in Georgia this number rises to 80%. Low awareness about the infection not only puts many people at risk of long-term liver damage, it also means that they may unknowingly transmit the virus to others.
Greater commitment from policy-makers, health care officials and health care providers is needed to raise awareness about HCV and to facilitate and improve early diagnosis. France is a clear example of the positive impact that public awareness campaigns can have. Currently, an estimated 56% of those infected know that they have the infection, compared with 24% in 1994 (17) .
It is equally important to improve diagnostic services for HCV and to make testing and counselling accessible and affordable. Though testing availability, access to health care and diagnostics policies were not considered in the framework of this study, a recent study on HCV in central and eastern Europe suggests that such services are not readily available, especially for risk groups such as IDUs (18) .
Current transmission routes also suggest that HCV has become an increasingly important health issue among IDUs. Due to the particular efficacy of transmission of HCV through the sharing of infected injecting equipment, it is estimated that after 5 years of exposure, the majority of IDUs may acquire HCV (19) . Therefore, the prevalence of HCV among IDUs is extremely high, reaching up to 80 to 90% in some European countries (18) . Despite being the group with the highest risks of HCV transmission, there is inadequate prevention, treatment and care for IDUs − especially across the new European Union member states, Russia and other eastern European countries. An assessment focusing on HCV among IDUs showed that in most of the countries in central and eastern Europe, IDUs do not have access to testing and counselling. HCV services are poorly linked to established health services for IDUs and there is a generally low level of HCV research within IDU communities and into ongoing risk behaviours (18) . IDUs are also systematically denied the HCV treatment, care and support that they need.
International guidelines clearly state that active drug use cannot be an exclusion criterion (1, 20) , yet in at least 9 out of 13 countries of the region drug use is identified as a contraindication to HCV treatment. One of the few exceptions is Slovenia, where drug users with health insurance can access treatment and be treated by multidisciplinary teams of specialists in infectious diseases and addiction treatment (18) . Therefore, effective management of HCV in Europe is not possible without a greater commitment to address the needs of IDUs, including a scale-up of harm reduction services and the linking of HCV testing and counselling to existing harm reduction services.
HCV coinfection with HIV is also common among active and former IDUs, who may acquire both viruses from injecting drugs. Such coinfection reduces the chance of recovery from acute HCV, compromises the effectiveness of existing HCV treatment and accelerates the progression of HCV infection to cirrhosis and liver failure (21) . Liver disease is also becoming one of the leading causes of death in people living with HIV and AIDS (1). In European countries high HCV prevalence among IDUs living with HIV has been reported from Russia (93% among HIV-positive IDUs in Togliatty) and Poland (90% among HIV positive IDUs in Bialystok); in Spain, three estimates ranged from 48% to 95% (18) (19) (20) (21) (22) .
